University of Ioannina
Επίδραση κυκλικών και υβριδικών πεπτιδικών αναλόγων του υποδοχέα ιντεγκρίνη IIβΙΙΙα σε ένα μοντέλο πειραματικής αρτηριακής θρόμβωσης σε κουνέλια
Abstract
dc:descriptionPlatelet activation and aggregation is the responsible mechanism for coronary syndromes. In this process, the αIIbβ3 receptor is the final pathway. Consequently, αIIbβ3 antagonists are of therapeutic importance. Two synthetic peptides, the highly constrained cyclic (S,S) PSRCDCR-NH2 and YMESRADR have exhibited strong in vivo and ex vivo antiplatelet effects in an electrically-induced carotid artery thrombosis model in rabbits. In the clinical setting, potent antiplatelet therapy with minimal bleeding adverse events is of paramount importance. Agents currently in use are effective in treating and preventing arterial thrombotic events but present with increased bleeding rates. In the current experimental study, we investigated the effect of the combined administration of each peptide with aspirin. Previously studied effective doses of YMESRADR and (S,S) PSRCDCR-NH2 were administrated in combination with an ineffective aspirin dose (5 mg/kg), to investigate their possible synergistic antiplatelet effect and bleeding side effects.Ethics Committee of the University of Ioannina, Greece, approved this study. Initially, citrated blood was collected by the rabbit’s ear artery. Aspirin was then administered per os. Subsequently, the peptide was infused (half of the studied dose as a bolus and the rest continuously over 90 min) through the femoral vein. Concentrations were 7.5 mg/kg and 12 mg/kg for YMESRADR, as well as 6 mg/kg and 12 mg/kg for (S,S) PSRCDCR-NH2 (groups A, B, C and D respectively, mean age 82.55±1.66 days for all animals). Carotid artery was then surgically isolated and baseline blood flow was monitored. One hour after infusion initiation, another blood sample was collected from the animal. Thrombosis was then electrically induced through the external carotid surface, to initiate thrombus formation. The experiment ended 90 min after electrical stimulation if the artery remained patent. Bleeding parameters were evaluated, to assess compound safety. For ex vivo measurements, platelet aggregation in PRP was conducted for each blood sample using arachidonic acid and ADP. Its inhibition was calculated for each agonist separately.Carotid’s patency was significantly preserved until the end of the experiment for all groups compared to placebo’s and aspirin’s groups. Furthermore, groups A and B also presented with blood flows significantly preserved compared to the animals treated only with the respective peptide doses. This effect was not observed for groups C and D. Inhibition of platelet aggregation was significantly augmented for all four groups of animals compared to the placebo’s and aspirin’s groups. Importantly, for group A the ADP-induced platelet aggregation was also significantly inhibited compared to the animals treated only with the respective peptide dose, which was not observed for groups B, C and D. The administered compounds were safe as bleeding assays were not prolonged in any group. In summary, combining the two peptides with 5 mg/kg aspirin is safe and effective. Only groups A and B presented with a significantly amplified clinical effect compared to the animals treated only with the respective YMESRADR dose. Among them, only group A was also escorted by a statistically significant ex vivo effect.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Englezopoulos, Konstantinos
- Εγγλεζόπουλος, Κωνσταντίνος
Subjects
dc:subject × 19- Αντιαιμοπεταλιακοί παράγοντες
- Αθηροθρόμβωση
- Συνθετικά πεπτίδια
- YMESRADR
- (S,S) PSRCDCR-NH2
- Antiplatelet aggents
- Atherothrombosis
- Χημεία
- Φυσικές Επιστήμες
- Χημεία, γενικά
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Chemical Sciences
- Natural Sciences
- Chemistry, general
- Clinical Medicine
- Medical and Health Sciences
- Cardiology and Cardiovascular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51561